Page 7 - Aurobindo Behera News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Aurobindo behera. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Aurobindo Behera Today - Breaking & Trending Today

Sun Pharma, Dr Reddy's, Aurobindo recall products in the U.S. market

Dr Reddy s Laboratories is recalling 2,24,710 (500 count) bottles of Atorvastatin Calcium tablets.
Leading home grown drug makers Sun Pharma, Dr Reddy s Laboratories, Aurobindo Pharma and Jubilant Pharma are recalling products in the U.S. market, the world s largest market for pharmaceutical products, for various reasons.
As per the latest Enforcement Report by the U.S. Food and Drug Administration (USFDA), Sun Pharma is recalling Cequa ophthalmic solution, which is used to treat chronic dry eye.
The U.S.-based subsidiary of the Mumbai-based drug major is recalling 37,400 cartons (60 vials per carton) of the ophthalmic solution for being subpotent , the U.S. health regulator said. ....

United States , Andhra Pradesh , Sun Pharma , Aurobindo Pharma , Jubilant Cadista Pharmaceuticals , Drug Administration , Jubilant Life Sciences , Jubilant Pharma , Enforcement Report , Atorvastatin Calcium , Progesterone Capsules , Salisbury Based Jubilant Cadista Pharmaceuticals , Cadista Pharmaceuticals , Singapore Based Jubilant Pharma , Noida Based Jubilant Life , Us Food And Drug Administration , Dr Reddy 39 S , Product Recall , Pharmaceutical Products , Dr Reddy 39s Laboratories , ஒன்றுபட்டது மாநிலங்களில் , ஆந்திரா பிரதேஷ் , சூரியன் பார்மா , அரவிந்தோ பார்மா , மகிழ்ச்சி வாழ்க்கை அறிவியல் , மகிழ்ச்சி பார்மா ,

Aurobindo Pharma Ltd eases for fifth straight session

Read more about Aurobindo Pharma Ltd eases for fifth straight session on Business Standard. Aurobindo Pharma Ltd is quoting at Rs 851.3, down 1.32% on the day as on 13:19 IST on the NSE. The stock jumped 89.11% in last one year as compared to a 42.9% rally in NIFTY and a 58.89% spurt in the Nifty Pharma index. ....

Aurobindo Pharma Ltd , Nifty Pharma , Pharma Ltd , Capital Market , Nifty 50 , National Stock Exchange Of India , Aurobindo Pharma , Economy Of India , Stock Exchanges , Bse Sensex , Integrated Circuits , Pharmaceuticals Nec , S Ampp Bse Sensex Index , Prince Edward Island , Nifty Pharma Index , Nnifty 50 Index , அரவிந்தோ பார்மா லிமிடெட் , நிஃப்டி பார்மா , பார்மா லிமிடெட் , மூலதனம் சந்தை , தேசிய ஸ்டாக் பரிமாற்றம் ஆஃப் இந்தியா , அரவிந்தோ பார்மா , பொருளாதாரம் ஆஃப் இந்தியா , ஸ்டாக் பரிமாற்றங்கள் , ஒருங்கிணைந்த சுற்றுகள் , மருந்துகள் கழுத்து ,

Investors turn to pharma stocks amid market crash; Nifty Pharma gains 1.5%

Read more about Investors turn to pharma stocks amid market crash; Nifty Pharma gains 1.5% on Business Standard. Among individual stocks, Lupin zoomed 3.4 per cent in the intra-day trade and hit a high of Rs 1,060, Sun Pharmaceuticals advanced 2 per cent, and Dr Reddy s Labs gained 1.7 per cent. ....

Sun Pharmam , Siddhant Khandekar , Aurobindo Pharma , Sun Cipla , Sun Pharmaceuticals , Dr Reddy Labs , National Stock Exchange , Nifty Pharma , Cadila Healthcare , Divis Labs , Production Linked Incentive , Global Manufacturing Turnover , Shilpa Medicare , Pharma Stocks , Pharma Sector , Market Selloff , Market Update , Market Crash , Market News , Pli Scheme , சித்தாந்த் கண்டெகர் , அரவிந்தோ பார்மா , சூரியன் சிப்லா , சூரியன் மருந்துகள் , டாக்டர் சிவப்பு ஆய்வகங்கள் , தேசிய ஸ்டாக் பரிமாற்றம் ,

Aurobindo net rises fourfold on U.S. sale

Updated:
Share Article
AAA
Aurobindo Pharma on Wednesday reported a fourfold jump in third-quarter consolidated profit to ₹2,946.3 crore, boosted mainly by one-time gains from the sale of a step-down subsidiary in the U.S.
Excluding exceptional items (net of tax), the consolidated net profit after JV share and minority interest was ₹836.6 crore, an almost 17% increase, the drugmaker said.
Revenue from operations rose 8% to ₹6,364.9 crore, the company said.
The board had approved an interim dividend of 150% or ₹1.50 per share, Aurobindo added.
MD N. Govindarajan said the company firm maintained growth momentum in revenue and profitability despite COVID-19 challenges. “We are witnessing a steady progress in our speciality pipeline and continue to focus on growing our business, improving efficiencies and productivity, he said. ....

Aurobindo Pharma , Eugia Pharma Specialties , அரவிந்தோ பார்மா ,

Aurobindo gains 5% on govt nod for promotion of manufacturing bulk drugs

Shares of Aurobindo Pharma rose 5 per cent to Rs 966 in intra-day trade on the BSE on Monday, thus gaining 7 per cent in the past two trading days, on report that the government has given the company approval under the Production Linked Incentive (PLI) scheme for promotion of domestic manufacturing of critical bulk drugs. The PLI scheme aims at promotion of manufacturing of critical key starting materials (KSMs)/drug intermediates and APIs in the country.
According to a report by
Press Trust of India, Aurobindo Pharma (through Lyfius Pharma) received government approval for setting up plants for production of Penicillin-G and 7-ACA, with committed production capacity of 15,000 MT and 2,000 MT, respectively under the PLI scheme. ....

Qule Pharma , Lyfius Pharma , Aurobindo Pharma , Production Linked Incentive , Press Trust , Erythromycin Thiocyanate , Aurobindo Phamra Share Price , Bulk Drugs , Aurobindo Pharma Latest News , அரவிந்தோ பார்மா , ப்ரொடக்ஶந் இணைக்கப்பட்டுள்ளது ஊக்கத்தொகை , ப்ரெஸ் நம்பிக்கை , அரவிந்தோ பாம்ர பகிர் ப்ரைஸ் , மொத்தமாக மருந்துகள் , அரவிந்தோ பார்மா சமீபத்தியது செய்தி ,